CDK

MD, Complement as hoppy 🤓

[CDK @d_kreu]

https://t.co/zZlrefWUt0

[CDK @d_kreu]

https://t.co/P1g33MBgU8

[The Conflict Desk 📰🌍 @TheConflictDesk]

‘We left dad in Kyiv’: This young Ukrainian boy describes fleeing his home as his father stays behind to fight for #Ukraine.

#Ukraine

[CDK @d_kreu]

@bruce_w92 @BiotechElmo @crist_phd @BillMiller32 Not a fan of cause. Hard to tell w little info, from Bofas report issues seems fixable. HSCT-TMA severity, no options and Narsoplimab efficiency and safety it would be more than odd if FDA all of the sudden dumbs the drug. At these prices a little to late to sell, so I'm waiting.

[CDK @d_kreu]

@Quantisnow @jpmorgan FDA ended the study due to impressive response rate, target 15%, Narsoplimab got +60% respons rate.

Lack of comparator? There is no treatment today only management that dosent work. Best case 15% response r... https://t.co/R3FXntVsAt

[CDK @d_kreu]

@flora_peyvandi @aHUSUKvoice #Narsoplimab FTW 🥇
Only complement inhibitior that addresses the crosslink between complement and coagulation 🔗
https://t.co/1o1AUjVPPn

[EIS Threat @EisThreat]

An increase in #complement activation has been observed in #GVHD and #HSCT-TMA, and rates of overlap between steroid-refractory GVHD and HSCT-TMA have approached 80%. The presence of both impacts clinical outcomes. #TMA #transplant https://t.co/dv7R38L4zF

[CDK @d_kreu]

@DanBrickner2 @roumenina @AegeanConf But yes I Spy will bring us the answer very soon
https://t.co/jlHOXOHDuZ

[CDK @d_kreu]

@DanBrickner2 @roumenina @AegeanConf Conference have neglected that terminal complement inhibition have failed over and over again in #covid19? Now cherry picking pts for successful outcome?
Look UP in the cascade guys, its where the real magic is happening #masp2inhibition #complementtherapies #Narsoplimab

[CDK @d_kreu]

@MikeyG_DDS Not used to twitter I guess. Good luck with the FDA 🤞 😄

[CDK @d_kreu]

Now we just need FDA to also end $RLFTF EUA delusions and forecast is complete 🎳 #covid19 #xbi #endothelialinjury #key

[CDK @d_kreu]

$cydy $hgen $RLFTF which company is the biggest #Covid_19 fraud? All very good at changing endpoint and data management to perfection 💯 👌

[CDK @d_kreu]

@zachiscards Where do you see any prayers? Scamming less intelligent investors and potential regulars to believe they have a covid19 treatment, now that's disgusting 🤢

[CDK @d_kreu]

@andrewkwil @TOWiU2 @anflan88 @SnackBioTech Hard to tell from a slide summary. Fact is a paper detailing the pivotal has been submitted for publication and will be published. Lot of answers will be provided. Answers FDA already has.

[CDK @d_kreu]

@andrewkwil @TOWiU2 @anflan88 @SnackBioTech Yes Andrew these slides are what Omeros submitted to FDA in the BLA. Fact are we don't know what FDA wanted and what Omeros answered.

[CDK @d_kreu]

@CKJsocial @FPoppelaars @aHUSAllianceAct @NationalaHUS Brought to you by Alexion Pharmaceutical
https://t.co/t5aZBN8tL3

[CDK @d_kreu]

@RWMaloneMD Why did you enter the study then? Whole idea is to build on a backbone of drugs that have proven to work.
But you run a RCT alone vs SOC and show the superiority of your wonderdrug..

[CDK @d_kreu]

@TOWiU2 @anflan88 @parrotfishing @Rajt1111 No SOC today, you can ⏸ the CNI(causes endothelial damage) but not effective & risk of GVHD ⬆️. Then there is a bunch of stuff that doesn't work well: steroids, c5i, plasma exchange ect. Reason why Narsoplimab only needs to beat 15% response rate.

[CDK @d_kreu]

@SnackBioTech Of course but this is TA-TMA, ultra orphan condition and w 90% mortality rate without treatment in the high risk setting.

And was it by a factor 3 or 4 Narsoplimab outperformed the FDA agreed threshold of approval?